Journal
CURRENT MEDICINAL CHEMISTRY
Volume 18, Issue 19, Pages 2960-2968Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986711796150450
Keywords
mTOR; mTORC1; mTORC2; AKT; ovarian cancer; rapamycin; rapalogs; everolimus; temsirolimus; ATP-competitive mTOR inhibitors
Ask authors/readers for more resources
The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growth-inhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available